Alexion Pharmaceuticals, Inc.

Oklahoma Medical Research Foundation

Selexys Pharmaceuticals Corporation

Russell P Rother

Paul P Tamburini

Douglas L Sheridan

Yuchun Zhang

Scott A Rollins

Mark James Evans

Leonard Bell

Stephen P Squinto

Dayang Wu

Louis A Matis

Susan Faas McKnight

Rodger P McEver

Jeremy P Springhorn

Susan Faas Mcknight

Yan Yan

Camille Bedrosian

Richard Alvarez

Ziad Kawar

Andrea Illingworth

Mayur Movalia

Steven H Nye

James M Mason

William L Fodor

Eileen Elliott Mueller

James A Wilkins

Hao Wang

Hugh Willison

Susan Halstead

Thomas C Thomas

Zhen Zhong

Eileen Mueller

Zhen (deceased) Zhong

Rodger P Mcever

Ziad S Kawar

Yi Wang

The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.

Methods and compositions for treating complement-associated disorders

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Anti-C5A antibodies

The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.

Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disorders

Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.

Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Anti-C5a antibodies

Methods of producing anti-C5a antibodies

The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.

Therapeutic methods using anti-CD200 antibodies

Methods for treating complement-associated disorders

This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.

Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Methods of treating complement-associated disorders with anti-C5a antibodies

Growing community of inventors

Oklahoma City, OK, United States of America

Russell P Rother